Livzon Pharmaceutical Group Inc (1513.HK)
58.65HKD
24 Apr 2018
HK$1.20 (+2.09%)
HK$57.45
HK$57.50
HK$59.00
HK$57.45
1,455,165
799,022
HK$71.60
HK$35.92
Thu, Feb 8 2018
CORRECTED-BRIEF-Livzon Pharmaceutical Unit's JV Livzon Biologics' Capital Will Be Boosted By 600 Mln Yuan (Feb 7)
* SAYS CAPITAL AT UNIT'S JV LIVZON BIOLOGICS WILL BE BOOSTED BY 600 MILLION YUAN ($94.94 million) Source text in Chinese: http://bit.ly/2nMWH27 Further company coverage: ($1 = 6.3201 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)
BRIEF-Livzon Pharmaceutical Group Announces Proposed Cash Dividend Distribution & Share Issue
* RECEIVED NOTICE FROM SHAREHOLDER PROPOSING ISSUE OF 3 BONUS SHARES FOR EVERY 10 SHARES TO ALL SHAREHOLDERS
BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab
* PROPOSES TO ENTER AGREEMENT PURSUANT TO WHICH JOINCARE TO SELL 49% EQUITY INTERESTS IN LIVZON MAB FOR RMB294 MILLION Source text for Eikon: Further company coverage:
REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II
* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)
BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan
* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects
BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial
* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection
BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm
* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS
BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial
* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection
BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept
* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan
BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln
* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage: